x

Posted 26 January, 2022

XpresSpa Group, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:XSPA in a 8-K filed on 26 January, 2022.


  As previously reported by XpresSpa Group, Inc. (the "Company") in its Current Report on Form 8-K dated January 19, 2022 (the "January 19, 2022 8-K"), Douglas Satzman resigned as the President and Chief Executive Officer of the Company for personal reasons effective as of January 19, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of XpresSpa Group, Inc.
Business/Consumer Services • Consumer Services
XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.
Market Cap
$5.37M
View Company Details
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 


As previously reported by XpresSpa Group, Inc. (the "Company") in its Current Report on Form 8-K dated January 19, 2022 (the "January 19, 2022 8-K"), Douglas Satzman resigned as the President and Chief Executive Officer of the Company for personal reasons effective as of January 19, 2022.


On January 21, 2022, Mr. Satzman entered into a Separation Agreement and Release in favor of the Company (the "Separation and Release"), settling all claims related to his employment with the Company and under his Employment Agreement with the Company, dated as of February 19, 2019 (the "Employment Agreement"), and otherwise setting forth the terms and conditions of his separation from service with the Company and severance arrangements in connection therewith.


Under the terms of the Separation and Release, Mr. Satzman will receive (i) an amount equal to his current annual base salary ($475,000) as severance, payable over the 12-month period following January 21, 2022 in accordance with the Company's regular payroll schedule and (ii) if elected by Mr. Satzman, subsidization of COBRA continuation payments under the Company' group medical insurance plans until the earlier of January 31, 2023, the date he is eligible under another employer's heath plan or Medicare, or the expiration of the maximum COBRA continuation coverage period for which he eligible under law. The Separation and Release provides (i) that Mr. Satzman is entitled to incentive compensation of $168,341 attributable to calendar year 2021 (of which amount $10,000 represents expense reimbursement), as provided in his Employment Agreement, (ii) that the vesting of all stock options, RSUs and other stock-based awards outstanding held by Mr. Satzman as of the effective date of the Separation and Release vest immediately after such effective date, and (iii) for a general release in favor of the Company.


As previously reported, the Separation and Release effectuates Mr. Satzman's resignation a director of the Company and all of its subsidiaries. The previously reported appointment of Scott R. Milford as a member of the Board with an initial term expiring at the Company's 2022 Annual Meeting of Stockholders became effective as of January 21, 2022, the effective date of Mr. Satzman's resignation as a director. The information regarding Mr. Milford in the third through fifth paragraphs of Item 5.02 of the January 19, 2022 8-K is incorporated by reference herein. 


The foregoing description of the Separation Agreement and Release is qualified in its entirety by the full text of the agreement, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.